{"meta":{"query_hash":"abebaf0f6325","filters":{"venue":"Blood and Lymphatic Cancer Targets and Therapy"},"cohort_total":3,"direct_labels_cover":0,"predictions_cover":3,"exported":3,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/abebaf0f6325","api":"https://metacan.xera.ac/api/v1/cohort?venue=Blood+and+Lymphatic+Cancer+Targets+and+Therapy"},"results":[{"id":"W2052425543","doi":"10.2147/blctt.s44343","title":"MicroRNA dysregulation in B-cell non-Hodgkin lymphoma","year":2013,"lang":"en","type":"article","venue":"Blood and Lymphatic Cancer Targets and Therapy","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Lymphoma; microRNA; Hodgkin lymphoma; Immune dysregulation; Cancer research; Biology; Immunology; Genetics; Gene; Immune system","score_opus":0.005049668615530808,"score_gpt":0.21923653078871208,"score_spread":0.21418686217318128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052425543","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026398975,0.96492386,0.0018163729,0.00079271506,0.00042599812,0.000026418744,0.00017148948,0.00009095403,0.0053532617],"genre_scores_gemma":[0.1561219,0.83501315,0.0028411201,0.0008564071,0.0003823794,0.000059609985,0.00035773072,0.000017664575,0.004350047],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99989676,0.000026505137,0.000015900707,0.000019106415,0.00003081918,0.000010943361],"domain_scores_gemma":[0.99994767,0.000016264707,0.000013599705,0.0000016923435,0.000015075942,0.000005755897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020683187,0.00021391772,0.0003801662,0.00039848572,0.00012003604,0.00039949824,0.00013725527,0.00030527354,0.0010615633],"category_scores_gemma":[0.00023572505,0.00006517928,0.00016217673,0.0004410828,0.00012096851,0.00023369424,0.00023580373,0.00033201787,0.0005123158],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004230654,0.00007792573,0.0061225803,0.008869819,0.00021664746,0.0022653257,0.00025636976,0.00080074964,0.16200717,0.0042676697,0.01625303,0.79843956],"study_design_scores_gemma":[0.00009824772,0.00082381454,0.0322645,0.001650855,0.000520022,0.019802848,0.0003168585,0.0013437513,0.083033465,0.0038179501,0.8562793,0.000048355236],"about_ca_topic_score_codex":0.00018126647,"about_ca_topic_score_gemma":0.00028440673,"teacher_disagreement_score":0.0010615633,"about_ca_system_score_codex":0.0002462021,"about_ca_system_score_gemma":0.00024467285,"threshold_uncertainty_score":0.0035512447},"labels":[],"label_agreement":null},{"id":"W2498089677","doi":"10.2147/blctt.s84157","title":"Waldenström macroglobulinemia: biology, genetics, and therapy","year":2016,"lang":"en","type":"review","venue":"Blood and Lymphatic Cancer Targets and Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Stephen's University","funders":"","keywords":"Ibrutinib; Waldenstrom macroglobulinemia; Bruton's tyrosine kinase; Medicine; Lymphoplasmacytic Lymphoma; Rituximab; Oncology; Lymphoma; Macroglobulinemia; CXCR4; Internal medicine; Germline mutation; Cancer research; Immunology; Leukemia; Chronic lymphocytic leukemia; Biology; Mutation; Tyrosine kinase; Genetics; Multiple myeloma; Receptor","score_opus":0.06055768449692186,"score_gpt":0.3826594748749941,"score_spread":0.32210179037807224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498089677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07993923,0.7794657,0.0035393778,0.05136369,0.003260012,0.00011483063,0.0003310071,0.00039474855,0.081591405],"genre_scores_gemma":[0.6429956,0.29127866,0.007797085,0.015530812,0.007328317,0.00020348864,0.0007500161,0.000055500284,0.034060474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998493,0.00003308716,0.000011924515,0.000015974032,0.000059618367,0.000030024636],"domain_scores_gemma":[0.99987507,0.000021093103,0.000029242368,0.000004930609,0.000022689974,0.000047008085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038669736,0.0004926529,0.00038988548,0.000579173,0.00031397335,0.00078760285,0.00031080988,0.00075256574,0.0018267793],"category_scores_gemma":[0.00056333374,0.00008518283,0.00017375409,0.00042991995,0.00043031026,0.00038486344,0.00049788004,0.0011288228,0.0010479849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035669736,0.0002904184,0.009950854,0.0006205675,0.00007114613,0.006830821,0.000117211355,0.000808773,0.009205976,0.012332911,0.09162208,0.8677925],"study_design_scores_gemma":[0.00034199204,0.0011379432,0.018285243,0.0013449672,0.00011042906,0.03893325,0.00012738253,0.0021250783,0.007606432,0.011110694,0.9188139,0.00006274495],"about_ca_topic_score_codex":0.0006169857,"about_ca_topic_score_gemma":0.001293591,"teacher_disagreement_score":0.0018267793,"about_ca_system_score_codex":0.0009754986,"about_ca_system_score_gemma":0.0005845772,"threshold_uncertainty_score":0.007077813},"labels":[],"label_agreement":null},{"id":"W2772944194","doi":"10.2147/blctt.s132060","title":"Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects","year":2017,"lang":"en","type":"review","venue":"Blood and Lymphatic Cancer Targets and Therapy","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Interleukin-3 receptor; Plasmacytoid dendritic cell; Myeloid leukemia; Medicine; Venetoclax; Immunotherapy; Myeloid; Leukemia; Lymphoma; Oncology; Immunology; Cancer research; Internal medicine; Cancer; Dendritic cell; Immune system; Chronic lymphocytic leukemia","score_opus":0.06908194046716576,"score_gpt":0.3568258328567061,"score_spread":0.28774389238954035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772944194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000098744495,0.9975539,0.00008582769,0.0011739369,0.00037887142,0.0000022008921,0.000011820823,0.000008065792,0.0006866058],"genre_scores_gemma":[0.0005744213,0.9980344,0.00014028868,0.00047091383,0.0003888822,0.0000030118026,0.000021150288,0.0000014537703,0.0003655024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981815,0.000033215398,0.000035669025,0.000031582356,0.000059469046,0.000021993477],"domain_scores_gemma":[0.9992131,0.00034192033,0.00009606166,0.000022518328,0.00024111789,0.00008538769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007503991,0.00054037047,0.001173023,0.0022815003,0.00035950128,0.0012792825,0.00078983925,0.0012482397,0.004551438],"category_scores_gemma":[0.0012979247,0.0002260127,0.00054577657,0.0020775036,0.00058185734,0.00244593,0.00071593554,0.0020880399,0.0017148295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007602185,0.00006077539,0.00028563972,0.017213173,0.000057020992,0.00040368552,0.00009355799,0.00032235915,0.00095915265,0.0052462015,0.052267328,0.92301506],"study_design_scores_gemma":[0.000011494584,0.000051052484,0.0005962217,0.00509818,0.000091796115,0.0024339515,0.00013314796,0.00009004191,0.00016472655,0.003498108,0.9878143,0.000016999207],"about_ca_topic_score_codex":0.0010012101,"about_ca_topic_score_gemma":0.0021545219,"teacher_disagreement_score":0.004551438,"about_ca_system_score_codex":0.00063529843,"about_ca_system_score_gemma":0.0016998271,"threshold_uncertainty_score":0.015226066},"labels":[],"label_agreement":null}]}